ArticleJournal of genomics2018
Isolation and Identification of an Anthracimycin Analogue from
Article in Journal of genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Investigation on taxonomy, secondary metabolites and antibacterial activity of Streptomyces sediminicola sp. nov., a novel marine sediment-derived Actinobacteria.Microbial cell factories · 2024Article
- Natural Products from Singapore Soil-DerivedMolecules (Basel, Switzerland) · 2023Article
- Antibacterial Thiopeptide GE2270-Congeners fromMolecules (Basel, Switzerland) · 2022Article
- Antibacterial Spirotetronate Polyketides from anMolecules (Basel, Switzerland) · 2022Article
- Ten-step asymmetric total syntheses of potent antibiotics anthracimycin and anthracimycin B.Chemical science · 2022Article
- Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- CRISPR/Cas9 RNP-assisted validation of palmarumycin biosynthetic gene cluster inFrontiers in microbiology · 2022Article
- Enhancing the Discovery of Bioactive Secondary Metabolites From Fungal Endophytes Using Chemical Elicitation and Variation of Fermentation Media.Frontiers in microbiology · 2022Article
- Chemical elicitation as an avenue for discovery of bioactive compounds from fungal endophytes.Frontiers in chemistry · 2022Article
- Identification and engineering of 32 membered antifungal macrolactone notonesomycins.Microbial cell factories · 2020Article
- Genomics-driven discovery of a biosynthetic gene cluster required for the synthesis of BII-Rafflesfungin from the fungus Phoma sp. F3723.BMC genomics · 2019Article
- Hypoculoside, a sphingoid base-like compound from Acremonium disrupts the membrane integrity of yeast cells.Scientific reports · 2019Article
- Anthracimycin B, a Potent Antibiotic against Gram-Positive Bacteria Isolated from Cultures of the Deep-Sea ActinomyceteMarine drugs · 2018Article
- The 160K Natural Organism Library, a unique resource for natural products research.Nature biotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern medicine is unthinkable without antibiotics; yet, growing issues with microbial drug resistance require intensified search for new active compounds. Natural products generated by Actinobacteria have been a rich source of candidate antibiotics, for example anthracimycin that, so far, is only known to be produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.